Invion (ASX: IVX) Lights Up as Shares Surge 37% on Global Photosoft Deal

Invion’s Global Photosoft Play Positions It as a Leader in PDT

Invion (ASX: IVX) surged 37% today after announcing it has secured perpetual, exclusive global rights to the Photosoft™ therapy platform, significantly expanding its patented pipeline across both human and animal health applications, including oncology, infectious diseases, and cardiovascular disorders.

Under the new agreement, Invion now holds exclusive global ownership of Photosoft, giving it full control over the platform’s development and commercialisation. The therapy’s coverage spans a broad range of conditions such as cancer, infectious diseases, and atherosclerosis, positioning Invion as a more diversified player in the photodynamic therapy space.

The acquisition will be completed via an all-scrip transaction of up to 36.7 million IVX shares, to be issued in three milestone-based tranches. The deal remains subject to shareholder approval and an Independent Expert Report (IER) confirming that the transaction is “fair and reasonable.”

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

How Photo Dynamic Therapy Works

Photo Dynamic Therapy (PDT) is a medical treatment that uses two key components, a light-activated drug (called a photosensitiser) and a specific wavelength of light.

Here’s how it works: the photosensitiser is administered to the patient, either applied to the skin or delivered intravenously (IV). This drug then naturally accumulates in cancer cells or infected tissue, where it remains inactive until exposed to light.

Doctors then shine a controlled light of a specific colour (wavelength) onto the targeted area. When the photosensitiser absorbs this light, it triggers a chemical reaction that produces a highly reactive form of oxygen. This oxygen effectively destroys the targeted cells, killing the cancer or infection while minimising damage to surrounding healthy tissue.

Invion Targets $100B Market with Expanded Photosoft Platform

The addressable markets Invion is now targeting with its expanded Photosoft platform are enormous, and that’s what makes this development so exciting.

The oncology segment alone represents roughly a US$70 billion market opportunity, while the infectious disease indications, including HPV, periodontal (human and animal), and non-cancer eye diseases, combine to form another US$23 billion market. On top of that, the atherosclerosis and related cardiovascular applications, including plaque reduction and bacterial infections, add a further US$15 billion opportunity. Altogether, Invion is now positioned to target a total addressable market exceeding US$100 billion.

What’s particularly compelling is that several of these indications may qualify for Orphan Drug Designation in the U.S., giving Invion potential 7-year marketing exclusivity per indication along with accelerated FDA approval pathways.

The investor’s takeaway for IVX

The purchase of the patents and global rights to the Photosoft platform is a strong addition to Invion’s growth strategy. It significantly expands the company’s intellectual property portfolio and provides exposure to several high-value therapeutic markets, including oncology, infectious diseases, and cardiovascular disorders, representing a combined addressable market of over US$100 billion.

However, investors should remain mindful that this is an all-scrip transaction, and the company will need to demonstrate meaningful clinical progress and regulatory advancement to justify the recent share price re-rating.